%0 Journal Article
%A Trautwein, Nils Florian
%A Schwenck, Johannes
%A Jacoby, Johann
%A Reischl, Gerald
%A Fiz, Francesco
%A Zender, Lars
%A Dittmann, Helmut
%A Hinterleitner, Martina
%A la Fougère, Christian
%T Long-term prognostic factors for PRRT in neuroendocrine tumors.
%J Frontiers in medicine
%V 10
%@ 2296-858X
%C Lausanne
%I Frontiers Media
%M DKFZ-2023-01280
%P 1169970
%D 2023
%X Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER1) highlighted the need to identify patient-specific long-term prognostic markers to avoid unnecessary side effects and enable better treatment stratification. Therefore, we retrospectively analyzed prognostic risk factors in NET patients treated with PRRT.A total of 62 NET patients (G1: 33.9
%K 177Lu (Other)
%K DOTA-TATE (Other)
%K Ga-HA-DOTATATE (Other)
%K molecular tumor volume (Other)
%K neuroendocrine tumor (NET) (Other)
%K peptide receptor radionuclide therapy (PRRT) (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37359009
%2 pmc:PMC10288842
%R 10.3389/fmed.2023.1169970
%U https://inrepo02.dkfz.de/record/277115